Japan's Ministry Holds Strategy Meeting On Hepatitis Treatment
This article was originally published in PharmAsia News
Executive Summary
To promote the development of new drugs and treatment for viral hepatitis B and hepatitis C, the Ministry of Health, Labor and Welfare established a Hepatitis Treatment Strategy Council and will hold the first meeting May 27. The meeting will discuss such topics as reducing the side effects of current treatments, treatments for relapsing patients and the development of the next generation of antiviral and cirrhosis drugs. The meeting will also discuss measures such as increased budget funding and more basic research to encourage development of new therapeutic drugs. (Click here for more - Japanese language
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.